Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.

What the trial testedrandomised · 2026

Randomised comparison

−28%−29% to −27%

Bigger than 6 in 10 on the map

As reported

HR 0.72, 95% CI 0.71–0.73

the abstract, start to end

… in fatty liver index versus placebo (HR 0.72; 95% CI 0.71-0.73; P < 0.0001).

← favours treatmentfavours comparator →

could be chance

Liver & masld

HR 0.720.71–0.73

GLP-1 receptor agonistsLiver & MASLD

GLP-1 receptor agonists × liver & masldhelps?one trial

unlikelylikely

0.500.25 without it

← favours comparatorfavours treatment →

more certainless certain

1 / 5

2026

this papercites it